Abstract
The surface-enhanced laser desorption ionization (SELDI) technology is a promising approach not only for the research of biomarkers in the blood of patients in clinical applications but also in preclinical studies to assess the drug-induced toxicities. The optimization of the SELDI platform is a crucial step before running plasma samples from preclinical toxicity studies. First, mass spectrometer parameters such as the laser energy and ion focus mass values should be assessed in order to obtain the highest quality of spectra. Second, the coefficient of variation of the intensity, resolution, and signal-to-noise ratio of the peaks detected in reference samples should be evaluated and used as quality control criteria. Last, a systematic evaluation of technical bias such as the spot and chip position and the bioprocessor sequence number may be achieved using the appropriate multivariate statistical analyses.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Merchant, M., and Weinberger, S.R. (2000) Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 21, 1164–1167.
Adam, B.L, Qu, Y., Davis. J., Ward, M.D., Clements, M.A., Cazares, L.H., Semmes, O.J., Schellhammer, P.F., Yasui, Y., Feng, Z., and Wright, G.L. Jr. (2002). Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 62, 3609–3614.
Petricoin, E.F., Ardekani, A.M., Hitt, B.A., Levine, P.J., Fusaro, V.A., Steinberg, S.M., Mills, G.B., Simone, C., Fishman, D.A., Kohn, E.C., and Liotta, L.A. (2002). Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572–577.
Ward, D.G., Suggett, N., Cheng, Y., Wei, W., Johnson, H., Billingham, L.J., Ismail, T., Wakelam, M.J., Johnson, P.J., and Martin, A. (2006). Identification of serum biomarkers for colon cancer by proteomic analysis. Br. J. Cancer 94, 1898–1905.
Carrette, O., Demalte, I., Scherl,. A, Yalkinoglu, O., Corthals, G., Burkhard, P., Hochstrasser, D.F., and Sanchez, J.C. (2003). A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer’s disease. Proteomics 8, 1486–1494.
Florian-Kujawski, M., Hussain, W., Chyna, B., Kahn, S., Hoppensteadt, D., Leya, F., and Fareed, J. (2004). Biomarker profiling of plasma from acute coronary syndrome patients. Application of ProteinChip array analysis. Int. Angiol. 3, 246–254.
Wetmore, B.A., and Merrick, B.A. (2004). Toxicoproteomics: proteomics applied to toxicology and pathology. Toxicol. Pathol. 32, 619–642.
Dare, T.O., Davies, H.A., Turton, J.A., Lomas, L., Williams, T.C., and York, M.J. (2002). Application of surface-enhanced laser desorption/ionization technology to the detection and identification of urinary parvalbumin-alpha: a biomarker of compound-induced skeletal muscle toxicity in the rat. Electrophoresis 18, 3241–3251.
White, C.N., Zhang, Z., and Chan, D.W. (2005). Quality control for SELDI analysis. Clin. Chem. Lab. Med. 43, 125–126.
Rodland, K.D. (2004). Proteomics and cancer diagnosis: the potential of mass spectrometry. Clin. Biochem. 7, 579–583.
Semmes, O.J., Feng, Z., Adam, B.L., Banez, L.L., Bigbee, W.L., Campos, D., Cazares, L.H., Chan, D.W., Grizzle, W.E., Izbicka, E., Kagan, J., Malik, G., McLerran, D., Moul, J.W., Partin, A., Prasanna, P., Rosenzweig, J., Sokoll, L.J., Srivastava, S., Srivastava, S., Thompson, I., Welsh, M.J., White, N., Winget, M., Yasui, Y., Zhang, Z., and Zhu, L. (2005). Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin. Chem. 51, 102–112.
Coombes, K.R., Fritsche, H.A. Jr., Clarke, C., Chen, J.N., Baggerly, K.A., Morris, J.S., Xiao, L.C., Hung, M.C., and Kuerer, H.M. (2003). Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization. Clin. Chem. 49, 1615–1623.
Hong, H., Dragan, Y., Epstein, J., Teitel, C., Chen, B., Xie, Q., Fang, H., Shi, L., Perkins, R., and Tong, W. (2005) Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of flight (TOF) mass spectrometry (MS). BMC Bioinformatics 6, Suppl 2:S5.
Baggerly, K.A., Morris, J.S., and Coombes, K.R. (2004) Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 20, 777–785.
Liggett, W.S., Barker, P.E., Semmes, O.J., and Cazares, L.H. (2004). Measurement reproducibility in the early stages of biomarker development. Dis. Markers 6, 295–307
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Léonard, JF., Courcol, M., Gautier, JC. (2011). Optimization of SELDI for Biomarker Detection in Plasma. In: Gautier, JC. (eds) Drug Safety Evaluation. Methods in Molecular Biology, vol 691. Humana Press. https://doi.org/10.1007/978-1-60761-849-2_22
Download citation
DOI: https://doi.org/10.1007/978-1-60761-849-2_22
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60327-186-8
Online ISBN: 978-1-60761-849-2
eBook Packages: Springer Protocols